| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Experimental Transplantation and Immunology, Division of Clinical Sciences, National Cancer Institute-Frederick Cancer Research and Development Center (NCI-FCRDC);
Intramural Research Support Program, Science Applications International Corporation (IRSP, SAIC) Frederick;
Data Management Services, NCI-FCRDC; and
§
Laboratory of Experimental Immunology, Division of Basic Sciences, NCI-FCRDC, Frederick, MD 21702
IL-12 is a potent immunoregulatory cytokine that has been shown to mediate tumor regression in a variety of tumor models. We describe the construction of AdCMV-IL-12, a recombinant adenovirus that encodes both subunits of IL-12 under transcriptional control of the CMV promoter. This recombinant virus efficiently infects a wide variety of cell types leading to the production of high levels of biologically active IL-12. Because the liver is a primary site of infection after i.v.-administered adenovirus, we tested the therapeutic efficacy of this virus in a murine hepatic metastasis tumor model. Systemic administration of AdCMV-IL-12 dramatically inhibited the formation of 3-day Renca hepatic metastases (mean of 16 metastases per liver) compared with the control virus AdCMV-ßgal (mean of 209) or vehicle alone (mean of 272). Histologic analysis indicated that metastatic growth inhibition was accompanied by a dramatic perivascular infiltrate consisting of T cells, macrophages, and neutrophils. Therapeutic efficacy was not diminished in animals depleted of CD4+ or CD8+ T cells, or in SCID mice, even after NK cell ablation. In the latter case, a hepatic perivascular infiltrate composed of macrophages and neutrophils was observed after AdCMV-IL-12-treatment, while numerous activated Kupffer cells were noted in the hepatic parenchyma. Analysis of therapy-induced changes in hepatic gene expression demonstrated increased levels of IP-10 and Mig RNAs, but no increase in iNOS, Fas, or FasL RNA levels was observed. Our data suggest a model of metastatic growth inhibition mediated by nonlymphocyte effector cells including macrophages and neutrophils and that may involve anti-angiogenic chemokines.
This article has been cited by other articles:
|
|
 |
|
  S. M. Meeran, S. Katiyar, C. A. Elmets, and S. K. Katiyar Interleukin-12 Deficiency Is Permissive for Angiogenesis in UV Radiation-Induced Skin Tumors Cancer Res., April 15, 2007; 67(8): 3785 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Meeran, S. K. Mantena, S. Meleth, C. A. Elmets, and S. K. Katiyar Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol. Cancer Ther., April 1, 2006; 5(4): 825 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, E. A. Lafleur, N. V. Koshkina, L. L. Worth, M. S. Lester, and E. S. Kleinerman Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity Mol. Cancer Res., December 1, 2005; 3(12): 685 - 692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Harada, M. Shimada, S. Okano, T. Suehiro, Y. Soejima, Y. Tomita, and Y. Maehara IL-12 Gene Therapy Is an Effective Therapeutic Strategy for Hepatocellular Carcinoma in Immunosuppressed Mice J. Immunol., December 1, 2004; 173(11): 6635 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kozar, R. Kaminski, T. Switaj, T. Oldak, E. Machaj, P. J. Wysocki, A. Mackiewicz, W. Lasek, M. Jakobisiak, and J. Golab Interleukin 12-based Immunotherapy Improves the Antitumor Effectiveness of a Low-Dose 5-Aza-2'-Deoxycitidine Treatment in L1210 Leukemia and B16F10 Melanoma Models in Mice Clin. Cancer Res., August 1, 2003; 9(8): 3124 - 3133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamori, M. Iwahashi, M. Nakamura, K. Ueda, X. Zhang, and H. Yamaue Intensification of Antitumor Effect by T Helper 1-dominant Adoptive Immunogene Therapy for Advanced Orthotopic Colon Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2357 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zhang and L. J. DeGroot Gene Therapy of a Rat Follicular Thyroid Carcinoma Model with Adenoviral Vectors Transducing Murine Interleukin-12 Endocrinology, April 1, 2003; 144(4): 1393 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ortaldo and H. A. Young Expression of IFN-{gamma} Upon Triggering of Activating Ly49D NK Receptors In Vitro and In Vivo: Costimulation with IL-12 or IL-18 Overrides Inhibitory Receptors J. Immunol., February 15, 2003; 170(4): 1763 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, X. Zhang, and X. Xia Regression of Tumor Growth and Induction of Long-Term Antitumor Memory by Interleukin 12 Electro-Gene Therapy J Natl Cancer Inst, May 15, 2002; 94(10): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. DeGroot and R. Zhang CLINICAL REVIEW 131: Gene Therapy for Thyroid Cancer: Where Do We Stand? J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2923 - 2928. [Full Text] [PDF]
|
|
|
|
|
|
E. A. Lafleur, S.-F. Jia, L. L. Worth, Z. Zhou, L. B. Owen-Schaub, and E. S. Kleinerman Interleukin (IL)-12 and IL-12 Gene Transfer Up-Regulate Fas Expression in Human Osteosarcoma and Breast Cancer Cells Cancer Res., May 1, 2001; 61(10): 4066 - 4071. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. C. Russell Update on adenovirus and its vectors J. Gen. Virol., November 1, 2000; 81(11): 2573 - 2604. [Full Text]
|
|
|
|
|
|
S. A. Ali, C. S. McLean, M. E. G. Boursnell, G. Martin, C. L. Holmes, S. Reeder, C. Entwisle, D. M. Blakeley, J. G. Shields, S. Todryk, et al. Preclinical Evaluation of "Whole" Cell Vaccines for Prophylaxis and Therapy Using a Disabled Infectious Single Cycle-Herpes Simplex Virus Vector to Transduce Cytokine Genes Cancer Res., March 1, 2000; 60(6): 1663 - 1670. [Abstract] [Full Text]
|
|
|
|
|
|
R. M. Minter, J. E. Rectenwald, K. Fukuzuka, C. L. Tannahill, D. La Face, V. Tsai, I. Ahmed, E. Hutchins, R. Moyer, E. M. Copeland III, et al. TNF-{alpha} Receptor Signaling and IL-10 Gene Therapy Regulate the Innate and Humoral Immune Responses to Recombinant Adenovirus in the Lung J. Immunol., January 1, 2000; 164(1): 443 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Watanabe, R. G. Fenton, J. M. Wigginton, K. L. McCormick, K. M. Volker, W. E. Fogler, P. G. Roessler, and R. H. Wiltrout Intradermal Delivery of IL-12 Naked DNA Induces Systemic NK Cell Activation and Th1 Response In Vivo That Is Independent of Endogenous IL-12 Production J. Immunol., August 15, 1999; 163(4): 1943 - 1950. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
